We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

112 hedge funds and large institutions have $197M invested in Aldeyra Therapeutics in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 40 increasing their positions, 25 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more call options, than puts

Call options by funds: $2.18M | Put options by funds: $825K

125% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 8

68% more capital invested

Capital invested by funds: $117M → $197M (+$79.7M)

60% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 25

9% more funds holding

Funds holding: 103112 (+9)

1.89% more ownership

Funds ownership: 59.47%61.37% (+1.9%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
112
Holders Change
+9
Holders Change %
+8.74%
% of All Funds
1.61%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
18
Increased
40
Reduced
25
Closed
8
Calls
$2.18M
Puts
$825K
Net Calls
+$1.36M
Net Calls Change
+$492K

ALDX Hedge Fund Activity: Q3 2024 in Review

112 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2024, worth a combined $197M — up 68% from $117M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ALDX positions and 8 closed out — a net gain of 10 holders — while 40 added to existing stakes and 25 trimmed.

The largest buyer was Invesco, adding an estimated $2.98M. The largest seller was Renaissance Technologies, cutting an estimated $1.88M.

  • 112 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2024, up from 103 in Q2 2024.
  • Funds reported $197M of Aldeyra Therapeutics stock for Q3 2024, up 68% quarter-over-quarter.
  • 18 funds opened new Aldeyra Therapeutics positions in Q3 2024 and 8 closed out, a net change of +10 holders.
  • The largest Aldeyra Therapeutics buyer in Q3 2024 was Invesco, an estimated $2.98M added.
  • The largest Aldeyra Therapeutics seller in Q3 2024 was Renaissance Technologies, an estimated $1.88M sold.

Based on aggregated 13F filings for Q3 2024.